Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 283 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retina Pathology Clear all
Completed Phase 1Phase 2 Interventional

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

NCT03780257
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
QR-421a, Sham-procedure (dose cohort 1&2 only)
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular Reactivity.

NCT00259701
View directory record Official record
Conditions
Diabetes, Retinopathy, Vascular Pathology
Interventions
Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2006 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jun 26, 2026, 5:00 AM EDT
Active, not recruiting No phase listed Observational

Impact of Non-Exudative Type 1 MNV on AMD Progression

NCT06125977
View directory record Official record
Conditions
Age-Related Macular Degeneration, Neovascularization, Choroidal
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
73 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Propranolol for Diabetic Retinopathy

NCT01535495
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Propranolol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Not applicable Interventional

Cataract Removal and Alzheimer's Disease

NCT00921297
View directory record Official record
Conditions
Cataracts, Alzheimer's Disease
Interventions
Immediate Cataract Surgery
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

NCT05158296
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
Ultevursen, Sham-procedure
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jun 26, 2026, 5:00 AM EDT
Recruiting Not applicable Interventional

Factors in Learning And Plasticity: Macular Degeneration

NCT05454124
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Training visual sensitivity, Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational

Natural History Study of CEP290-Related Retinal Degeneration

NCT03396042
View directory record Official record
Conditions
Blindness, Leber Congenital Amaurosis 10, Vision Disorders, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration
Interventions
Not listed
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
3 Years to 99 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 3 Interventional

Preventing Depression in Patients With Macular Degeneration

NCT00042211
View directory record Official record
Conditions
Depression, Macular Degeneration
Interventions
Problem Solving Treatment, Control
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
65 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration

NCT00001615
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Corticosteroid
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

NCT00336323
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Photocoagulation, Bevacizumab
Procedure · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

NCT02966145
View directory record Official record
Conditions
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Visual Function Study

NCT00001346
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Vision, Subnormal
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 5:00 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

NCT01193504
View directory record Official record
Conditions
Pseudophakia, Cataract Surgery
Interventions
Pred Forte, Lotemax
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Laguna Hills, California • Miami, Florida • Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

NCT04597632
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

NCT01205035
View directory record Official record
Conditions
Retinal Diseases, Telangiectasis
Interventions
ranibizumab 2.0mg
Drug
Lead sponsor
Eye Center of Northern Colorado, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jun 26, 2026, 5:00 AM EDT
Terminated Phase 1 Interventional

Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

NCT03396861
View directory record Official record
Conditions
Irvine-Gass Syndrome
Interventions
Aflibercept
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jun 26, 2026, 5:00 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549
View directory record Official record
Conditions
Geographic Atrophy of the Macula
Interventions
GAL-101, Placebo
Drug
Lead sponsor
Galimedix Therapeutics Inc
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 26, 2026, 5:00 AM EDT
Suspended Not applicable Interventional

Chromatic Retinal Stimulation to Reduce Chronic Pain and Pain Sensitivity

NCT05956067
View directory record Official record
Conditions
Chronic Low-back Pain, Chronic Pain, Fibromyalgia
Interventions
Green Light stimulation, Equal Energy White stimulation, S-cone modulating white light
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 1Phase 2 Interventional

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

NCT01570790
View directory record Official record
Conditions
Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV, Choroidal Neovascularization
Interventions
Combretastatin A-4 Phosphate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jun 26, 2026, 5:00 AM EDT
Not listed Not applicable Interventional

A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye

NCT01531842
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
Interventions
Conj flora Antibiotic resistance
Procedure
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2012 · Synced Jun 26, 2026, 5:00 AM EDT
Completed No phase listed Observational

Vitamin Replacement in Abetalipoproteinemia

NCT00004574
View directory record Official record
Conditions
Abetalipoproteinemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 5:00 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

NCT06270836
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Tarcocimab, Sham injection
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 26, 2026, 5:00 AM EDT